01 7Xiaflex
Collagenase Clostridium Histolyticum
Main Therapeutic Indication : Musculoskeletal
Currency : USD
2020 Revenue in Millions : 316
2019 Revenue in Millions : 328
Growth (%) : -3
Collagenase Clostridium Histolyticum
Main Therapeutic Indication : Musculoskeletal
Currency : USD
2021 Revenue in Millions : 432
2020 Revenue in Millions : 316
Growth (%) : 37
Collagenase Clostridium Histolyticum
Main Therapeutic Indication : Musculoskeletal
Currency : USD
2022 Revenue in Millions : 439
2021 Revenue in Millions : 432
Growth (%) : 1
Collagenase Clostridium Histolyticum
Main Therapeutic Indication : Musculoskeletal
Currency : USD
2023 Revenue in Millions : 475
2022 Revenue in Millions : 439
Growth (%) : 8
Collagenase Clostridium Histolyticum
Main Therapeutic Indication : Bone and Joint Diseases
Currency : USD
2017 Revenue in Millions : 213
2016 Revenue in Millions : 190
Growth (%) : 12
Collagenase Clostridium Histolyticum
Main Therapeutic Indication : Bone And Joint Diseases
Currency : USD
2018 Revenue in Millions : 264
2017 Revenue in Millions : 213
Growth (%) : 24%
Collagenase Clostridium Histolyticum
Main Therapeutic Indication : Musculoskeletal
Currency : USD
2019 Revenue in Millions : 328
2018 Revenue in Millions : 265
Growth (%) : 24
